The abstract is read at the publisher; the summary is JClub's.
A modified Delphi of 32 international experts reached consensus on 15 antibody-validation actions that are both effective and feasible for implementation by 2030.
- Why it matters: Unvalidated, context-inappropriate antibody use is linked to major research waste in the United States and consumes many animal and human samples with potentially unreliable conclusions. Existing frameworks and initiatives lack a consensus action plan specifying stakeholder responsibilities, timing, and priority.
- What they did: Experts from academia, publishers, funders, manufacturers, and institutional leadership rated 33 proposed actions on 9-point effectiveness and feasibility scales across two Delphi rounds, using the RAND/UCLA Appropriateness Method for consensus.
- The result: Fifteen items were judged effective and feasible by 2030, spanning institutional, funder, publisher, manufacturer, and cross-stakeholder roadmap actions, while 15 were effective but feasibility was uncertain and one was rejected.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.